Literature DB >> 16800746

Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs).

Katerina Oikonomopoulou1, Kristina K Hansen, Mahmoud Saifeddine, Nathalie Vergnolle, Illa Tea, Michael Blaber, Sachiko I Blaber, Isobel Scarisbrick, Eleftherios P Diamandis, Morley D Hollenberg.   

Abstract

We tested the hypothesis that human tissue kallikreins (hKs) may regulate signal transduction by cleaving and activating proteinase-activated receptors (PARs). We found that hK5, 6 and 14 cleaved PAR N-terminal peptide sequences representing the cleavage/activation motifs of human PAR1 and PAR2 to yield receptor-activating peptides. hK5, 6 and 14 activated calcium signalling in rat PAR2-expressing (but not background) KNRK cells. Calcium signalling in HEK cells co-expressing human PAR1 and PAR2 was also triggered by hK14 (via PAR1 and PAR2) and hK6 (via PAR2). In isolated rat platelets that do not express PAR1, but signal via PAR4, hK14 also activated PAR-dependent calcium signalling responses and triggered aggregation. The aggregation response elicited by hK14 was in contrast to the lack of aggregation triggered by hK5 and 6. hK14 also caused vasorelaxation in a phenylephrine-preconstricted rat aorta ring assay and triggered oedema in an in vivo model of murine paw inflammation. We propose that, like thrombin and trypsin, the kallikreins must now be considered as important 'hormonal' regulators of tissue function, very likely acting in part via PARs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16800746     DOI: 10.1515/BC.2006.104

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  35 in total

Review 1.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

2.  Kallikrein 6 is a novel molecular trigger of reactive astrogliosis.

Authors:  Isobel A Scarisbrick; Maja Radulovic; Joshua E Burda; Nadya Larson; Sachiko I Blaber; Caterina Giannini; Michael Blaber; Alexander G Vandell
Journal:  Biol Chem       Date:  2012-04       Impact factor: 3.915

Review 3.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

4.  Neutrophil Elastase Activates Protease-activated Receptor-2 (PAR2) and Transient Receptor Potential Vanilloid 4 (TRPV4) to Cause Inflammation and Pain.

Authors:  Peishen Zhao; TinaMarie Lieu; Nicholas Barlow; Silvia Sostegni; Silke Haerteis; Christoph Korbmacher; Wolfgang Liedtke; Nestor N Jimenez-Vargas; Stephen J Vanner; Nigel W Bunnett
Journal:  J Biol Chem       Date:  2015-04-15       Impact factor: 5.157

5.  Induction of complement C3a receptor responses by kallikrein-related peptidase 14.

Authors:  Katerina Oikonomopoulou; Robert A DeAngelis; Hui Chen; Eleftherios P Diamandis; Morley D Hollenberg; Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

Review 6.  Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems.

Authors:  Kristina K Hansen; Katerina Oikonomopoulou; Yang Li; Morley D Hollenberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-19       Impact factor: 3.000

7.  Proteinase-activated receptor 2 stimulates Na,K-ATPase and sodium reabsorption in native kidney epithelium.

Authors:  Luciana Morla; Gilles Crambert; David Mordasini; Guillaume Favre; Alain Doucet; Martine Imbert-Teboul
Journal:  J Biol Chem       Date:  2008-08-04       Impact factor: 5.157

8.  Cathepsin S elicits itch and signals via protease-activated receptors.

Authors:  Vemuri B Reddy; Steven G Shimada; Parul Sikand; Robert H Lamotte; Ethan A Lerner
Journal:  J Invest Dermatol       Date:  2010-01-14       Impact factor: 8.551

9.  KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease.

Authors:  Allison C Billi; Jessica E Ludwig; Yi Fritz; Richard Rozic; William R Swindell; Lam C Tsoi; Dennis Gruzska; Shahla Abdollahi-Roodsaz; Xianying Xing; Doina Diaconu; Ranjitha Uppala; Maya I Camhi; Philip A Klenotic; Mrinal K Sarkar; M Elaine Husni; Jose U Scher; Christine McDonald; J Michelle Kahlenberg; Ronald J Midura; Johann E Gudjonsson; Nicole L Ward
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

10.  Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome.

Authors:  Anaïs Briot; Céline Deraison; Matthieu Lacroix; Chrystelle Bonnart; Aurélie Robin; Céline Besson; Pierre Dubus; Alain Hovnanian
Journal:  J Exp Med       Date:  2009-05-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.